Lundbeck files for EMA approval of vortioxetine for depression

Friday, September 21, 2012 01:34 PM

H. Lundbeck, an international pharmaceutical company, has submitted a marketing authorization application (MAA) to the EMA for the approval of the investigational multimodal antidepressant vortioxetine (Lu AA21004), and the dossier has been accepted for review.

Vortioxetine belongs to a new generation of antidepressants that has been developed for the treatment of patients with major depressive episodes (MDE). The data package supporting the file is substantial, consisting of 10 large, placebo-controlled clinical short and long term studies in major depression using dosages from 5mg to 20mg of vortioxetine. This data package includes studies in relapse prevention and in elderly patients with major depression.

More than 5,000 individuals have been exposed to vortioxetine worldwide, including the U.S., across the entire clinical trial program. Vvortioxetine was generally well-tolerated, with the most common adverse event being nausea.

Lundbeck plans to submit a new drug submission (NDS) to Health Canada for vortioxetine during the second half of this year as well. Separately, Lundbeck and Takeda, its partner in the U.S. and Japan, plan to submit am NDA to the FDA during the fourth quarter of 2012 and in Japan during 2013. 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 17

PPD, Medidata join their technologies for risk-based monitoring, adaptive trial design

ERT acquires eClinical Insights in "strategic combination" to gain cloud-based trial software platform, expertise

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs